 <Drug namemain="Temozolomide" id="108485">
    <NamesCode>
      <Name>CCRG-81045</Name>
      <Name>M&amp;B-39831</Name>
      <Name>NSC-362856</Name>
      <Name>Sch-52365</Name>
    </NamesCode>
    <NamesBrand>
      <Name>Temodal</Name>
      <Name>Temodar</Name>
    </NamesBrand>
    <NamesGeneric>
      <Name>Temozolomide</Name>
    </NamesGeneric>
    <MechanismsMolecular>
      <Mechanism id="4076">DNA Topoisomerase II alpha Inhibitors</Mechanism>
      <Mechanism id="1895">DNA Alkylating Drugs</Mechanism>
      <Mechanism id="1895">TEP II Inhibitors</Mechanism>
    </MechanismsMolecular>
    <DevelopmentStatusSummary>
      <Row>
        <Condition id="1325">Neurologic cancer</Condition>
        <PhaseHighest sort="18" id="6">Launched</PhaseHighest>
        <ConditionInActiveDevelopment>No</ConditionInActiveDevelopment>
        <Year>2010</Year>
        <Organizations>
          <Organization id="424">Merck &amp; Co.</Organization>
        </Organizations>
        <AdministrationRoutes>
          <AdministrationRoute id="48">parenteral</AdministrationRoute>
        </AdministrationRoutes>
      </Row>
      <Row>
        <Condition id="582">Astrocytoma</Condition>
        <PhaseHighest sort="18" id="6">Launched</PhaseHighest>
        <ConditionInActiveDevelopment>No</ConditionInActiveDevelopment>
        <Year>1999</Year>
        <Organizations>
          <Organization id="424">Merck &amp; Co.</Organization>
        </Organizations>
        <AdministrationRoutes>
          <AdministrationRoute id="3">intravenous</AdministrationRoute>
          <AdministrationRoute id="1">oral</AdministrationRoute>
        </AdministrationRoutes>
    </Row>
    </DevelopmentStatusSummary>
</Drug>
